Objective To conduct a meta-analysis of the efficacy and safety of 225Ac-PSMA-617 in the
treatment of metastatic castration-resistant prostate cancer based on existing clinical …

Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most
prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this …

Abstract Background In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …

Simple Summary Prostate cancer (PC) is one of the most common malignancies in men.
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) hybrid …

For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival
benefit of classic treatment options with chemotherapy and drugs targeting androgen …

Introduction The prostate-specific membrane antigen (PSMA) targeted radioligand therapy
(PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients …

Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …

Bone is the most common metastatic site in prostate cancer (PCa). 68Ga-PSMA-11 (or
gozetotide) and sodium fluoride-18 (Na18F) are rather new radiopharmaceuticals for …

Non-metastatic castration-resistant prostate cancer (nmCRPC) indicates a condition
characterized by the progression of the prostate-specific antigen without radiographic …

In recent years, the prostate-specific membrane antigen (PSMA) has achieved a significant
role in the diagnostics and treatments of patients with prostate cancer. Guidelines by the …